showcase_img

Because childhood and young adult cancer is different

The types and driving genetic aberrations of these malignancies are different than those affecting the adult population, so a specifically designed, targeted but comprehensive panel is needed to advance clinical research and drive understanding and future precision oncology therapeutic solutions.

Request info      Download the flyer

The Ion Torrent Oncomine Childhood Cancer Research Assay is a next-generation sequencing (NGS)-based tool designed for comprehensive genomic profiling of cancers affecting children and young adults.

Comprehensive panel design:

  • Compiled by leading researchers and pediatric oncologists
  • 203 unique genes including thousands of fusion drivers (and comprehensive mutation coverage)

Optimised workflow for fast results:

  • End-to-end solution including informatics
  • 2–3 days, depending on sample type
  • Compatible with different sample types enabled including blood, bone marrow, and FFPE tissue

Covers relevant targets for a broad range of malignancies affecting children and adults:

  • Childhood leukemias
  • Lymphomas
  • Sarcomas
  • Central nervous system and brain neoplasms
OCCRA content
Featured videos

Understanding pediatric and childhood cancers

NGS research panels for pediatric cancer

Read the latest interview with Dr. Tim Triche featured in the Pathologist

The Oncomine Childhood Cancer Research Assay is the first cancer panel designed for all forms of childhood cancer, including leukemia, brain tumors, and a diverse group of solid tumors. Of particular importance, it assays both RNA and DNA, which allows one to detect both gene fusions and DNA mutations, both of which are important in childhood cancer.

Timothy Triche, MD, PhD
Founding Director of the Children’s Hospital Los Angeles Center for Personalized Medicine


Oncomine Childhood Cancer Research workflow
 Oncomine-Childhood-Cancer-Research-Assay-Sample-to-Answer-Workflow

The end-to-end workflow optimized for childhood cancer research enables the analysis of a variety of sample types including blood and bone marrow, fresh/frozen tissue, and  FFPE tissue in 2–3 days from sample to result. Up to eight samples can be multiplexed on a single Ion 540 Chip*, allowing for flexibility in batch size.

Comprehensive mutation coverage (86)

ABL1
ABL2
ALK
ACVR1
AKT1
ASXL1
ASXL2
BRAF
CALR
CBL
CCND1
CCND3
CCR5
CDK4
CIC
CREBBP
CRLF2
CSF1R
CSF3R
CTNNB1
DAXX
DNMT3A
EGFR
EP300
ERBB2
ERBB3
ERBB4
ESR1
EZH2
FASLG
FBXW7
FGFR1
FGFR2
FGFR3
FLT3
GATA2
GNA11
GNAQ
H3F3A
HDAC9
HIST1H3B
HRAS
IDH1
IDH2
IL7R
JAK1
JAK2
JAK3
KDM4C
KDR
KIT
KRAS
MAP2K1
MAP2K2
MET
MPL
MSH6
MTOR
MYC
MYCN
NCOR2
NOTCH1
NPM1
NRAS
NT5C2
PAX5
PDGFRA
PDGFRB
PIK3CA PIK3R1
PPM1D
PTPN11
RAF1
RET
RHOA
SETBP1
SETD2
SH2B3
SH2D1A
SMO
STAT3
STAT5B
TERT
TPMT
USP7
ZMYM3

Full exon coverage(44)

APC
ARID1A
ARID1B
ATRX
CDKN2A
CDKN2B
CEBPA
CHD7
CRLF1
DDX3X
DICER1
EBF1
EED
FAS
GATA1
GATA3
GNA13
ID3
IKZF1
KDM6A
KMT2D
MYOD1
NF1
NF2
PHF6
PRPS1
PSMB5
PTCH1
PTEN
RB1
RUNX1
SMARCA4
SMARCB1
SOCS2
SUFU
SUZ12
TCF3
TET2
TP53
TSC1
TSC2
WHSC1
WT1
XIAP

CNV (28)

ABL2
ALK
BRAF
CCND1
CDK4
CDK6
EGFR
ERBB2
ERBB3
FGFR1
FGFR2
FGFR3
FGFR4
GLI1
GLI2
IGF1R
JAK1
JAK2
JAK3
KIT
KRAS
MDM2
MDM4
MET
MYC
MYCN
PDGFRA
PIK3CA

Fusion and expression (98)

ABL1
ABL2
AFF3
ALK
BCL11B
BCOR
BCR
BRAF
CAMTA1
CCND1
CIC
CREBBP
CRLF2
CSF1R
DUSP22
EGFR
ETV6
EWSR1
FGFR1
FGFR2
FGFR3
FLT3
FOSB
FUS
GLI1
GLIS2
HMGA2
JAK2
KAT6A
KMT2A
KMT2B
KMT2C
KMT2D
LMO2
MAML2
MAN2B1
MECOM
MEF2D
MET
MKL1
MLLT10
MN1
MYB
MYBL1
MYH11
MYH9
NCOA2
NCOR1
NOTCH1
NOTCH2
NOTCH4
NPM1
NR4A3
NTRK1
NTRK2
NTRK3
NUP214
NUP98
NUTM1
NUTM2B
PAX3
PAX5
PAX7
PDGFB
PDGFRA
PDGFRB
PLAG1
RAF1
RANBP17
RARA
RECK
RELA
RET
ROS1
RUNX1
SS18
SSBP2
STAG2
STAT6
TAL1
TCF3
TFE3
TP63
TSLP
TSPAN4
UBTF
USP6
WHSC1
YAP1
ZMYND11
ZNF384

Gene Expression
BCL2
BCL6
FGFR1
FGFR4
IGF1R
MET
MYCN
MYC
TOP2A

>1700 fusion isoform variants

The content of the Oncomine Childhood Research Assay has been developed with leading scientists and pediatric oncologists. It includes a large 97-gene translocation/fusion panel (>1700 fusion isophorme variants), as fusions are relatively more common in childhood sarcomas and leukemias, but also an  82-DNA target panel with comprehensive coverage of all relevant mutations, 44 targets with full exon  coverage, specifically tumor supressor genes, and 24 CNV targets.

  Catalog Number
Oncomine Childhood Cancer Research AssayChef-ready libraryLearn more and request quote ›
Oncomine Childhood Cancer Research AssayManual libraryLearn more and request quote ›

*The assay has been optimized and verified for the Ion 540 Chip. 

For Research Use Only. Not for use in diagnostic procedures.